CAR-T lymphocyte therapy targeting the CD19 antigen has been shown to be highly effective in the treatment of B-ALL, with complete remission rates between 70-90% in paediatric and adult patients (113). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.